Anthony G. Quinn
CIK 1532219 · President & CEO · last filed 2026-02-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
4
Total Filings
57
Lifetime Open-Market Net
-$6.48M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Generation Bio Co. (GBIO) Delisted | Director | 0 | $5.34 | $0 | $328.0K | 11 | 2026-02-09 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | President & CEO | 816,835 | $12.01 | $9.81M | $2.20M | 24 | 2022-03-18 |
| Kaleido Biosciences, Inc. (KLDO) Delisted | Director | 31,603 | $0.29 | $9.2K | $0 | 3 | 2021-07-01 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | EVP, CMO, & Head of R&D | 32,675 | — | — | -$9.01M | 19 | 2015-06-23 |
Recent Filings · Page 4 of 6
57 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-07-13 | Spyre Therapeutics, Inc. (AGLE) Delisted | Exer (M) | +3,307 | $18.1K | EDGAR |
| 2018-02-22 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-02-20 | Spyre Therapeutics, Inc. (AGLE) Delisted | Exer (M) | +15,211 | $83.1K | EDGAR |
| 2017-12-08 | Spyre Therapeutics, Inc. (AGLE) Delisted | Buy (P) | +8,288 | $41.1K | EDGAR |
| 2017-12-05 | Spyre Therapeutics, Inc. (AGLE) Delisted | Buy (P) | +17,121 | $83.2K | EDGAR |
| 2017-09-01 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-04-25 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-04-12 | Spyre Therapeutics, Inc. (AGLE) Delisted | Buy (P) | +10,000 | $100.0K | EDGAR |
| 2015-06-23 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Mixed | −32,637 | $3.0K | EDGAR |
| 2015-06-09 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Grant (A) | +27,000 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.